Abstract
Prognosis for women with epithelial ovarian cancer remains poor. One new molecular target in epithelial ovarian cancer is folate receptor alpha (FRα). This commentary discusses the characteristics that contribute to its attractiveness as a candidate for therapeutic intervention.
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Ovarian Epithelial / drug therapy*
-
Carcinoma, Ovarian Epithelial / metabolism
-
Carcinoma, Ovarian Epithelial / pathology
-
Clinical Trials as Topic
-
Female
-
Folate Receptor 1 / antagonists & inhibitors*
-
Humans
-
Molecular Targeted Therapy
-
Prognosis
Substances
-
Antineoplastic Agents
-
Folate Receptor 1